ThromboGenics announces positive data from 24-month followup study of Jetrea
Belgium-based ophthalmic medicine specialist ThromboGenics (Euronext Brussels: THR) has announced positive top-line results from its study of Jetrea (ocriplasmin).
The OASIS study is a randomized, sham-controlled, double-masked study following up patients for 24 months post-injection. It was designed to provide long-term controlled efficacy and safety data for Jetrea use in patients treated for symptomatic vitreomacular adhesion, and is the first study of its kind since the pivotal Phase III program.
The key findings were that 47.1% of patients treated with Jetrea achieved vitreomacular adhesion resolution at day 28 post-injection compared with 6.2% who received a sham injection, and that the safety profile at 24 months was consistent with the overall safety profile known from the approved label.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze